SciELO - Scientific Electronic Library Online

 
vol.36 issue5The pharmacological effect of Bothrops neuwiedii pauloensis (jararaca-pintada) snake venom on avian neuromuscular transmissionAntinociceptive activity of Hypericum caprifoliatum and Hypericum polyanthemum (Guttiferae) author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

  • English (pdf)
  • Article in xml format
  • How to cite this article
  • SciELO Analytics
  • Curriculum ScienTI
  • Automatic translation

Indicators

Related links

Share


Brazilian Journal of Medical and Biological Research

Print version ISSN 0100-879XOn-line version ISSN 1414-431X

Braz J Med Biol Res vol.36 no.5 Ribeirão Preto May 2003

http://dx.doi.org/10.1590/S0100-879X2003000500010 

Braz J Med Biol Res, May 2003, Volume 36(5) 625-629 (Short Communication)

Dopaminergic profile of new heterocyclic N-phenylpiperazine derivatives

G. Neves1,2, R. Fenner1, A.P. Heckler1, A.F. Viana1,2, L. Tasso2, R. Menegatti3,4, C.A.M. Fraga3,4, E.J. Barreiro3, T. Dalla-Costa2 and S.M.K. Rates1,2

1Laboratório de Psicofarmacologia, Departamento de Produção de Matéria-Prima, Faculdade de Farmácia, and 2Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil
3Laboratório de Avaliação e Síntese de Substâncias Bioativas, Faculdade de Farmácia, and 4Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil

Abstract
Text
References
Correspondence and Footnotes


Abstract

Dopamine constitutes about 80% of the content of central catecholamines and has a crucial role in the etiology of several neuropsychiatric disorders, including Parkinson's disease, depression and schizophrenia. Several dopaminergic drugs are used to treat these pathologies, but many problems are attributed to these therapies. Within this context, the search for new more efficient dopaminergic agents with less adverse effects represents a vast research field. The aim of the present study was to report the structural design of two N-phenylpiperazine derivatives, compound 4: 1-[1-(4-chlorophenyl)-1H-4-pyrazolylmethyl]-4-phenylhexahydropyrazine and compound 5: 1-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-ylmethyl]-4-phenylhexahydropyrazine, planned to be dopamine ligands, and their dopaminergic action profile. The two compounds were assayed (dose range of 15-40 mg/kg) in three experimental models: 1) blockade of amphetamine (30 mg/kg, ip)-induced stereotypy in rats; 2) the catalepsy test in mice, and 3) apomorphine (1 mg/kg, ip)-induced hypothermia in mice. Both derivatives induced cataleptic behavior (40 mg/kg, ip) and a hypothermic response (30 mg/kg, ip) which was not prevented by haloperidol (0.5 mg/kg, ip). Compound 5 (30 mg/kg, ip) also presented a synergistic hypothermic effect with apomorphine (1 mg/kg, ip). Only compound 4 (30 mg/kg, ip) significantly blocked the amphetamine-induced stereotypy in rats. The N-phenylpiperazine derivatives 4 and 5 seem to have a peculiar profile of action on dopaminergic functions. On the basis of the results of catalepsy and amphetamine-induced stereotypy, the compounds demonstrated an inhibitory effect on dopaminergic behaviors. However, their hypothermic effect is compatible with the stimulation of dopaminergic function which seems not to be mediated by D2/D3 receptors.

Key words: N-phenylpiperazine derivatives, Dopamine, Apomorphine hypothermia, Amphetamine stereotypy, Catalepsy


Dopamine belongs to the catecholamine neurotransmitter group and constitutes about 80% of the content of these substances in the brain. At least five different forms of dopamine receptors have been cloned from the brain. These receptors are divided into two classes: the D1-like class (including D1 and D5 receptors) and the D2-like class (including D2, D3 and D4 receptors), differentiated by anatomical, pharmacological and biochemical parameters (1).

Dopamine has a crucial role in the etiology of several neuropsychiatric disorders, including Parkinson's disease, depression and, mainly, schizophrenia. Schizophrenia is a chronic psychiatric illness that affects approximately 1% of the world population. Usually, a schizophrenic patient presents two main kinds of symptoms: positive (delusions, hallucinations) and negative (avolition, anhedonia, attentional impairment) symptoms. Most of the drugs used for treating this disorder are D2-like receptor antagonists and are called typical antipsychotics. These drugs are effective only for treating the positive symptoms and present an important profile of adverse effects, mainly the extrapyramidal disturbances such as tardive dyskinesia (2,3).

Clozapine (1) is an atypical antipsychotic drug with high affinity for D4 and 5-HT2 receptors that has a pharmacological profile different from that of classic antipsychotics, being effective in the treatment of positive and negative symptoms and lacking the extrapyramidal effects. On the other hand, clozapine (1) tends to induce agranulocytosis in 1 to 2% of the patients, which restricts its clinical use in patients that do not respond to classical therapy (2,4). For this reason, the search for new more efficient dopaminergic agents with lower adverse effects is still an extremely active research field.

New molecular templates presenting higher functional selectivity for dopamine receptors, such as NGD-94-1 (2) (Ki = 3.8 nM [D4]) and L-741 (3) (Ki = 2.1 nM [D2]) have been described (5,6). We have developed new N-phenylpiperazine derivatives with a potential dopaminergic profile by molecular hybridization of the lead compounds clozapine (1) (template D4) and L-741 (3) (template D2). The strategy for obtaining the structures of 1-[1-(4-chlorophenyl)-1H-4-pyrazolylmethyl]-4-phenylhexahydropyrazine (compound 4) and isosteric 1-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-ylmethyl]-4-phenylhexahydropyrazine (compound 5) is presented in Figure 1. Both compounds bind to dopamine rat brain receptors (Pereira EFR and Albuquerque EX, unpublished results). In the present study we evaluated the in vivo dopaminergic activity of compounds 4 and 5 in three animal models: blockade of amphetamine-induced stereotypy in rats, the catalepsy test in mice and apomorphine-induced hypothermia in mice.

Male Wistar rats (200 to 250 g) and male Swiss CF-1 mice (20 to 30 g), both from the breeding colony of Fundação Estadual de Produção e Pesquisa em Saúde (Porto Alegre, RS, Brazil), were used. The animals had free access to food and water and were kept at constant room temperature (22 ± 1ºC) under a 12-h light cycle (lights off at 7:00 pm). All drugs were administered by the intraperitoneal (ip) route (injection volume of 1 ml/kg rat body weight and 1 ml/100 g mouse body weight). Compounds 4 and 5 were suspended in saline with the aid of no more than 5% (v/v) polysorbate 80. The experimental groups consisted of at least 10 animals each.

Amphetamine-induced stereotypy was evaluated according to the protocol and doses described by Carlini (7). Thirty minutes after amphetamine (30 mg/kg, ip) administration, the results were scored from 0 to 3 according to increasing intensity of stereotypy (7). This behavior is classically blocked by drugs that inhibit the dopaminergic functions such as neuroleptics (D2 antagonists) (8). Conversely, atypical antipsychotics like clozapine (1) have little or no effect on stereotypy (9). The results are shown in Table 1. Only compound 4 (30 mg/kg, ip) significantly blocked the stereotyped behavior, although compound 5 (30 mg/kg, ip) also showed a tendency to block it.

The induction of catalepsy test was adapted from those described by Carlini (7). The mice were placed gently on a wood bar elevated 6.5 cm from the floor. The time spent by the animals in this position was measured 30 and 60 min after the treatments. The results are shown in Table 1. Both derivatives induced a time- and dose-dependent cataleptic behavior in the animals. Compound 5 presented a longer-lasting effect, indicating a possible pharmacokinetic difference between drugs. Despite having virtually no strength as an animal behavioral model for antipsychotics, catalepsy tests do have value in the study of neuropharmacology of extrapyramidal function and as a rapid behavioral screening for predicting the motor side effects of potentially antipsychotic drugs (10,11). The extrapyramidal side effects of antipsychotic drugs are related to a blockade of D2 striatal dopamine receptors (12). However, selective D1 blockers such as SCH23390 also induce marked catalepsy behavior in animals similar to those of opioids and cholinergic agonists (10).

To test the apomorphine (1 mg/kg ip)-induced hypothermia, two treatments were administered to each animal: the first one immediately after measuring the basal rectal temperature (T0) and the second one 30 min later. The rectal temperature was recorded 15 and 30 min after the second treatment (T45 and T60, respectively) (9,13). The results are shown in Table 2. A single administration of compounds 4 (30 mg/kg, ip) and 5 (30 mg/kg, ip) induced a hypothermic response which was not abolished by haloperidol (0.5 mg/kg, ip) administration. Furthermore, a synergistic hypothermic effect between apomorphine (1 mg/kg, ip) and compound 5 was demonstrated.

Production of hypothermia is a major pharmacological effect of apomorphine in animals. It has been demonstrated that, at low doses (1 mg/kg), this effect results from the direct agonistic action of apomorphine on both D1 and D2 dopamine receptors located in the temperature-regulating centers of the hypothalamus (13-15). Functional interaction between D1 and D2 receptors has been well documented and these receptors are generally considered to interact synergistically. Nevertheless, there is also evidence for independent roles of dopamine D1 and D2 receptors in thermoregulation (14,16). On the other hand, the role of serotonin receptors in thermoregulation should also be considered (17).

At the tested dose, haloperidol efficiently blocked the apomorphine effect on the core temperature of the animals. In contrast, it has been reported that higher doses of haloperidol induce a hypothermic response which is antagonized by the administration of 5-HT2 agonists (18). Thus, since haloperidol did not affect the N-phenylpiperazine derivative-induced hypothermia, it is plausible to suggest that the mechanism of the hypothermic effect of compounds 4 and 5 is other than dopamine D2/D3 receptor activation. A hypothermic effect that was not abolished by a selective D2 antagonist was also reported for the selective D1 agonist A68930 (14). In addition, it was reported that clozapine (1)-induced hypothermia in rats is blockaded by selective D1 antagonists, suggesting that this drug may be a partial D1 agonist (19,20). On the other hand, Menon et al. (15) demonstrated that the selective D1 antagonist SCH23390 was not effective in blocking the apomorphine-induced hypothermia but caused a potentiation of the hypothermic effect of quinpirole, a selective D2 agonist. Since compounds 4 and 5 were planned based on the chemical structure of clozapine, it is possible that their hypothermic effects are also mediated by D1 receptor occupation or, perhaps, by interaction with the serotonergic system. The hypothermic effects of compounds 4 and 5 have a magnitude comparable to that of subcutaneous 10 mg/kg clozapine in rats (20). Other experiments are in progress to elucidate the putative participation of D1 and 5-HT2 receptors in the hypothermic effect of N-phenylpiperazine derivatives.

In conclusion, the N-phenylpiperazine derivatives 4 and 5 seem to have a peculiar profile of action on dopaminergic functions. On the basis of the results of catalepsy and amphetamine-induced stereotypy, the compounds demonstrated an inhibitory effect on dopaminergic behaviors. However, their hypothermic effect is compatible with the stimulation of dopaminergic function which seems not to be mediated by D2/D3 receptors.


Figure 1. Rational structural design of N-phenylpiperazine derivatives 4 and 5 based on the structure of clozapine (1) and L-741 (3).

[View larger version of this image (25 K GIF file)]


References

1. Vallone D, Picetti R & Borrelli E (2000). Structure and function of dopamine receptors. Neuroscience and Biobehavioral Reviews, 24: 125-132.        [ Links ]

2. Baldessarini RJ (1996). Drugs and the treatment of psychiatric disorders: Psychosis and anxiety. In: Hardman JG & Limbird LE (Editors), Goodman & Gilman´s - The Pharmacological Basis of Therapeutics. 9th edn. McGraw-Hill, New York, NY, USA.        [ Links ]

3. Stahl P (2000). Essential Psychopharmacology - Neuroscientific Basis and Practical Applications. 2nd edn. Cambridge University Press, New York, NY, USA.        [ Links ]

4. Crismon ML & Dorson PG (1997). Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG & Posey LM (Editors), Pharmacotherapy - A Pathophysiological Approach. 3rd edn. Appleton & Lange, Stamford, UK.        [ Links ]

5. Thurkauf A, Yuan J, Chen X et al. (1997). 2-Phenyl-4(5)-[[4-(pyrimidin-2-yl)piperazin-1-yl]methyl]imidazole. A highly selective antagonist at cloned human D-4 receptors. Journal of Medicinal Chemistry, 40: 1-3.        [ Links ]

6. Kulagowski JJ, Broughton HB, Curtis NR et al. (1996). 3-[[4-(4-Chlorophenyl)piperazin-1-yl]-methyl]-1H -pyrrolo[2,3-b]pyridine: An antagonist with high affinity and selectivity for the human dopamine D4 receptor. Journal of Medicinal Chemistry, 39: 1941-1942.        [ Links ]

7. Carlini EA (1973). Farmacologia Prática sem Aparelhagens. Sarvier, São Paulo, SP, Brazil.        [ Links ]

8. Verma A & Kulkarni SK (1993). Differential role of dopamine receptor subtypes in thermoregulation and stereotypic behavior in naive and reserpinized rats. Archives Internationales de Pharmacodynamie et de Therapie, 324: 17-32.        [ Links ]

9. Moore NC & Gershon S (1989). Which atypical antipsychotics are identified by screening tests? Clinical Neuropharmacology, 12: 167-184.        [ Links ]

10. Sanberg PR, Bunsey MD, Giordano M & Norman A (1988). The catalepsy test: its ups and downs. Behavioral Neuroscience, 102: 748-759.        [ Links ]

11. Weiss JM & Kilts CD (1998). Animal models of depression and schizophrenia. In: Schatzberg AF & Nemeroff CB (Editors). Textbook of Psychopharmacology. American Psychiatric Press, Washington, DC, USA.        [ Links ]

12. Wadenberg M-LG, Soliman A, VanderSpek SC & Kapur S (2001). Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsycopharmacology, 25: 633-641.        [ Links ]

13. Salmi P, Jimenez P & Ahlenius S (1993). Evidence for specific involvement of dopamine D1 and D2 receptors in the regulation of body temperature in the rat. European Journal of Pharmacology, 236: 395-400.        [ Links ]

14. Puech AJ, Frances H & Simon P (1978). Imipramine antagonism of apomorphine-induced hypothermia: A non-dopaminergic interaction. European Journal of Pharmacology, 47: 125-127.        [ Links ]

15. Menon MK, Gordon LI, Kodama CK & Fitten J (1988). Influence of D1 receptor system on the D2-mediated hypothermic response in mice. Life Sciences, 43: 871-881.        [ Links ]

16. Salmi P (1998). Independent roles of dopamine D1 and D2/3 receptors in rat thermoregulation. Brain Research, 781: 188-193.        [ Links ]

17. Salmi P & Ahlenius S (1998). Evidence for functional interactions between 5-HT1A and 5-HT2A receptors in rat thermoregulatory mechanisms. Pharmacology and Toxicology, 82: 122-127.        [ Links ]

18. Yamada J, Sugimoto Y & Horisaka K (1995). Serotonin2 (5-HT2) receptor agonist 1(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlopromazine-induced and haloperidol-induced hypothermia in mice. Biological and Pharmaceutical Bulletin, 18: 1580-1583.        [ Links ]

19. Salmi P, Karlsson T & Ahlenius S (1994). Antagonism by SCH23390 of clozapine-induced hypothermia in the rat. European Journal of Pharmacology, 253: 67-73.        [ Links ]

20. Salmi P & Ahlenius S (1996). Further evidence for clozapine as a dopamine D1 receptor agonist. European Journal of Pharmacology, 307: 27-31.        [ Links ]


Correspondence and Footnotes

Address for correspondence: S.M.K. Rates, Faculdade de Farmácia, UFRGS, Av. Ipiranga, 2752, 90610-000 Porto Alegre, RS, Brasil. Fax: +55-51-3316-3417. E-mail: ratessmk@farmacia.ufrgs.br

Presented at the XVII Annual Meeting of the Federação de Sociedades de Biologia Experimental, Salvador, BA, Brazil, August 28-31, 2002. Research supported by PROCAD-CAPES. Received April 18, 2002. Accepted January 8, 2003.

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License